Cargando…
A FCGR3A Polymorphism Predicts Anti-drug Antibodies in Chronic Inflammatory Bowel Disease Patients Treated With Anti-TNF
Background. The production of anti-drug antibodies (ADAs) against IgG monoclonal antibodies (mAbs) targeting tumour necrosis factor (TNF) is an important cause of loss of response to anti-TNF mAbs in patients with inflammatory bowel diseases (IBD) such as Crohn's disease (CD) and ulcerative col...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765734/ https://www.ncbi.nlm.nih.gov/pubmed/29333082 http://dx.doi.org/10.7150/ijms.22812 |
_version_ | 1783292282741456896 |
---|---|
author | Romero-Cara, Patricia Torres-Moreno, Daniel Pedregosa, José Vílchez, Juan Antonio García-Simón, María Sergia Ruiz-Merino, Guadalupe Morán-Sanchez, Senador Conesa-Zamora, Pablo |
author_facet | Romero-Cara, Patricia Torres-Moreno, Daniel Pedregosa, José Vílchez, Juan Antonio García-Simón, María Sergia Ruiz-Merino, Guadalupe Morán-Sanchez, Senador Conesa-Zamora, Pablo |
author_sort | Romero-Cara, Patricia |
collection | PubMed |
description | Background. The production of anti-drug antibodies (ADAs) against IgG monoclonal antibodies (mAbs) targeting tumour necrosis factor (TNF) is an important cause of loss of response to anti-TNF mAbs in patients with inflammatory bowel diseases (IBD) such as Crohn's disease (CD) and ulcerative colitis (UC). Since receptors for the Fc portion of IgG (FCGRs) are involved in the degradation of IgG complexes, we hypothesised that a polymorphism in FCGR3A (V158F; rs396991) gene could be involved in anti-TNF ADA generation and treatment resistance. Material and Methods. A cohort of 103 IBD patients (80 CD, 23 UC) were genotyped and serum level of both anti-TNFs (infliximab or adalimumab) and ADA against them were measured. Results. No significant differences were observed between ADA occurrence or V158F genotype and type of disease or the kind of anti-TNF administrated. Interestingly, VV genotype correlated with patients producing ADA (VV: 37.5% vs. FV: 10.6% or FF: 5%; p=0.004) and was an independent predictor of this event after multivariate analysis. Moreover, VV genotype also correlated with those patients receiving anti-TNF dose intensification (p=0.03). Conclusion. FCGR3A V158F polymorphism seems to be associated with ADA production against mAbs and it could be taken into account when considering the dose and type of anti-TNF in IBD patients. |
format | Online Article Text |
id | pubmed-5765734 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-57657342018-01-14 A FCGR3A Polymorphism Predicts Anti-drug Antibodies in Chronic Inflammatory Bowel Disease Patients Treated With Anti-TNF Romero-Cara, Patricia Torres-Moreno, Daniel Pedregosa, José Vílchez, Juan Antonio García-Simón, María Sergia Ruiz-Merino, Guadalupe Morán-Sanchez, Senador Conesa-Zamora, Pablo Int J Med Sci Research Paper Background. The production of anti-drug antibodies (ADAs) against IgG monoclonal antibodies (mAbs) targeting tumour necrosis factor (TNF) is an important cause of loss of response to anti-TNF mAbs in patients with inflammatory bowel diseases (IBD) such as Crohn's disease (CD) and ulcerative colitis (UC). Since receptors for the Fc portion of IgG (FCGRs) are involved in the degradation of IgG complexes, we hypothesised that a polymorphism in FCGR3A (V158F; rs396991) gene could be involved in anti-TNF ADA generation and treatment resistance. Material and Methods. A cohort of 103 IBD patients (80 CD, 23 UC) were genotyped and serum level of both anti-TNFs (infliximab or adalimumab) and ADA against them were measured. Results. No significant differences were observed between ADA occurrence or V158F genotype and type of disease or the kind of anti-TNF administrated. Interestingly, VV genotype correlated with patients producing ADA (VV: 37.5% vs. FV: 10.6% or FF: 5%; p=0.004) and was an independent predictor of this event after multivariate analysis. Moreover, VV genotype also correlated with those patients receiving anti-TNF dose intensification (p=0.03). Conclusion. FCGR3A V158F polymorphism seems to be associated with ADA production against mAbs and it could be taken into account when considering the dose and type of anti-TNF in IBD patients. Ivyspring International Publisher 2018-01-01 /pmc/articles/PMC5765734/ /pubmed/29333082 http://dx.doi.org/10.7150/ijms.22812 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Romero-Cara, Patricia Torres-Moreno, Daniel Pedregosa, José Vílchez, Juan Antonio García-Simón, María Sergia Ruiz-Merino, Guadalupe Morán-Sanchez, Senador Conesa-Zamora, Pablo A FCGR3A Polymorphism Predicts Anti-drug Antibodies in Chronic Inflammatory Bowel Disease Patients Treated With Anti-TNF |
title | A FCGR3A Polymorphism Predicts Anti-drug Antibodies in Chronic Inflammatory Bowel Disease Patients Treated With Anti-TNF |
title_full | A FCGR3A Polymorphism Predicts Anti-drug Antibodies in Chronic Inflammatory Bowel Disease Patients Treated With Anti-TNF |
title_fullStr | A FCGR3A Polymorphism Predicts Anti-drug Antibodies in Chronic Inflammatory Bowel Disease Patients Treated With Anti-TNF |
title_full_unstemmed | A FCGR3A Polymorphism Predicts Anti-drug Antibodies in Chronic Inflammatory Bowel Disease Patients Treated With Anti-TNF |
title_short | A FCGR3A Polymorphism Predicts Anti-drug Antibodies in Chronic Inflammatory Bowel Disease Patients Treated With Anti-TNF |
title_sort | fcgr3a polymorphism predicts anti-drug antibodies in chronic inflammatory bowel disease patients treated with anti-tnf |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765734/ https://www.ncbi.nlm.nih.gov/pubmed/29333082 http://dx.doi.org/10.7150/ijms.22812 |
work_keys_str_mv | AT romerocarapatricia afcgr3apolymorphismpredictsantidrugantibodiesinchronicinflammatoryboweldiseasepatientstreatedwithantitnf AT torresmorenodaniel afcgr3apolymorphismpredictsantidrugantibodiesinchronicinflammatoryboweldiseasepatientstreatedwithantitnf AT pedregosajose afcgr3apolymorphismpredictsantidrugantibodiesinchronicinflammatoryboweldiseasepatientstreatedwithantitnf AT vilchezjuanantonio afcgr3apolymorphismpredictsantidrugantibodiesinchronicinflammatoryboweldiseasepatientstreatedwithantitnf AT garciasimonmariasergia afcgr3apolymorphismpredictsantidrugantibodiesinchronicinflammatoryboweldiseasepatientstreatedwithantitnf AT ruizmerinoguadalupe afcgr3apolymorphismpredictsantidrugantibodiesinchronicinflammatoryboweldiseasepatientstreatedwithantitnf AT moransanchezsenador afcgr3apolymorphismpredictsantidrugantibodiesinchronicinflammatoryboweldiseasepatientstreatedwithantitnf AT conesazamorapablo afcgr3apolymorphismpredictsantidrugantibodiesinchronicinflammatoryboweldiseasepatientstreatedwithantitnf AT romerocarapatricia fcgr3apolymorphismpredictsantidrugantibodiesinchronicinflammatoryboweldiseasepatientstreatedwithantitnf AT torresmorenodaniel fcgr3apolymorphismpredictsantidrugantibodiesinchronicinflammatoryboweldiseasepatientstreatedwithantitnf AT pedregosajose fcgr3apolymorphismpredictsantidrugantibodiesinchronicinflammatoryboweldiseasepatientstreatedwithantitnf AT vilchezjuanantonio fcgr3apolymorphismpredictsantidrugantibodiesinchronicinflammatoryboweldiseasepatientstreatedwithantitnf AT garciasimonmariasergia fcgr3apolymorphismpredictsantidrugantibodiesinchronicinflammatoryboweldiseasepatientstreatedwithantitnf AT ruizmerinoguadalupe fcgr3apolymorphismpredictsantidrugantibodiesinchronicinflammatoryboweldiseasepatientstreatedwithantitnf AT moransanchezsenador fcgr3apolymorphismpredictsantidrugantibodiesinchronicinflammatoryboweldiseasepatientstreatedwithantitnf AT conesazamorapablo fcgr3apolymorphismpredictsantidrugantibodiesinchronicinflammatoryboweldiseasepatientstreatedwithantitnf |